Canzon Israel Ltd Asset Resilience Ratio
Canzon Israel Ltd asset resilience ratio. Canzon Israel Ltd (CNZN) has an Asset Resilience Ratio of 0.73% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read CNZN current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Canzon Israel Ltd (2012–2023)
Asset resilience ratio of Canzon Israel Ltd from 2012 to 2023. This chart shows how Canzon Israel Ltd's Asset Resilience Ratio has changed over time. See Canzon Israel Ltd (CNZN) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Canzon Israel Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Canzon Israel Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA33.00K | 0.73% |
| Total Liquid Assets | ILA33.00K | 0.73% |
Asset Resilience Insights
- Limited Liquidity: Canzon Israel Ltd maintains only 0.73% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Canzon Israel Ltd Industry Peers by Asset Resilience Ratio
Compare Canzon Israel Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Canzon Israel Ltd Asset Resilience Ratio by Year (2012–2023)
Canzon Israel Ltd asset resilience ratio by year from 2012 to 2023. The table below shows the annual Asset Resilience Ratio data for Canzon Israel Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.49% | ILA26.00K ≈ $69.71 |
ILA5.25 Million ≈ $14.08K |
-0.89pp |
| 2022-12-31 | 1.39% | ILA137.00K ≈ $367.29 |
ILA9.89 Million ≈ $26.51K |
-6.99pp |
| 2021-12-31 | 8.37% | ILA1.10 Million ≈ $2.95K |
ILA13.13 Million ≈ $35.20K |
-11.61pp |
| 2016-12-31 | 19.98% | ILA1.86 Million ≈ $4.98K |
ILA9.30 Million ≈ $24.92K |
-0.15pp |
| 2015-12-31 | 20.13% | ILA1.80 Million ≈ $4.82K |
ILA8.93 Million ≈ $23.94K |
+6.55pp |
| 2014-12-31 | 13.57% | ILA1.25 Million ≈ $3.35K |
ILA9.21 Million ≈ $24.69K |
-5.33pp |
| 2013-12-31 | 18.90% | ILA2.86 Million ≈ $7.66K |
ILA15.13 Million ≈ $40.55K |
+3.93pp |
| 2012-12-31 | 14.97% | ILA3.24 Million ≈ $8.68K |
ILA21.61 Million ≈ $57.94K |
-- |
About Canzon Israel Ltd
Canzon Israel Ltd focuses on investing and managing projects in the field of initiating construction for residential and commercial purposes in Portugal. The company was formerly known as User Trend Ltd and changed its name into Canzon Israel Ltd in June 2019. Canzon Israel Ltd was incorporated in 1999 and is based in Tel Aviv, Israel.